p

PEPTIC ULCER

/ / 15 min read

Table of Contents

Introduction to Peptic Ulcer Disease

Peptic ulcer disease (PUD) refers to the presence of painful, open sores that develop in the inner lining of the gastrointestinal (GI) tract. Specifically, these lesions occur where the mucous membrane is exposed to acid and pepsin, typically affecting the esophagus (esophageal ulcers), the stomach (gastric ulcers), or the first part of the small intestine (duodenal ulcers). These ulcers represent a breakdown of the protective mucosal barrier that normally shields the underlying tissues from the corrosive effects of highly acidic digestive juices. While historically, peptic ulcers were often attributed to stress or diet, modern gastroenterology recognizes that the vast majority of cases stem from a complex interaction between microbial infection, primarily involving Helicobacter pylori (H. pylori), and the chronic use of certain medications, particularly nonsteroidal anti-inflammatory drugs (NSAIDs).

The prevalence of peptic ulcer disease has shifted dramatically since the late 20th century following the groundbreaking identification of H. pylori as the primary causative agent and the subsequent widespread adoption of effective eradication therapies. Despite this improvement in understanding and treatment, PUD remains a significant global health concern due to its potential for serious complications, including life-threatening hemorrhage, perforation, and obstruction. Understanding the pathophysiology, clinical presentation, and comprehensive management strategies for peptic ulcers is crucial for mitigating morbidity and mortality associated with this condition. The characteristic symptoms, which often involve intermittent upper abdominal pain described as burning or gnawing, frequently lead patients to seek medical attention, underscoring the substantial impact of PUD on quality of life and healthcare utilization.

A fundamental distinction exists between the three main types of peptic ulcers based on their location. Duodenal ulcers, which occur in the duodenum, are statistically the most common type and often present with pain that is relieved by eating but returns two to three hours later, a pattern related to the buffering effect of food on stomach acid. Conversely, gastric ulcers, located in the stomach lining, are often associated with pain that is exacerbated by eating. Esophageal ulcers, though less frequent, are typically linked to severe gastroesophageal reflux disease (GERD). Regardless of location, the formation of these ulcers invariably involves an imbalance where aggressive factors (acid, pepsin, H. pylori, NSAIDs) overwhelm the defensive mechanisms (mucus layer, bicarbonate secretion, and mucosal blood flow) designed to protect the delicate mucosal lining.

Etiology and Pathogenesis

The etiology of peptic ulcer disease is overwhelmingly dominated by two primary factors: chronic infection with the bacterium Helicobacter pylori and the regular use of nonsteroidal anti-inflammatory drugs (NSAIDs). H. pylori is a spiral-shaped, Gram-negative bacterium uniquely adapted to colonize the harsh, acidic environment of the human stomach. This microorganism achieves survival by producing large amounts of the enzyme urease, which hydrolyzes urea into ammonia and carbon dioxide, creating a localized cloud of neutralizing alkali around the bacteria. The resulting chronic inflammation (gastritis) damages the mucosal barrier, leading to increased acid secretion in some individuals and atrophy in others, ultimately resulting in ulcer formation. Furthermore, specific virulence factors of H. pylori, such as the cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA), contribute significantly to mucosal cell damage and the host inflammatory response.

The mechanism by which NSAIDs induce ulcers is distinct but equally damaging. NSAIDs inhibit cyclooxygenase (COX) enzymes, which are critical for the synthesis of prostaglandins. Prostaglandins serve a vital protective role in the gastric mucosa by promoting blood flow, stimulating mucus and bicarbonate production, and regulating epithelial repair. When these protective mechanisms are compromised through COX inhibition, the mucosa becomes highly susceptible to damage from gastric acid and pepsin. Factors that significantly increase the risk of NSAID-induced ulcers include advanced age, high NSAID dosage, concurrent use of corticosteroids or anticoagulants, and a prior history of peptic ulcer disease. Even low-dose aspirin, widely used for cardiovascular prophylaxis, carries a recognized risk of ulcerogenesis, necessitating careful risk assessment and prophylactic measures in vulnerable populations.

While H. pylori and NSAIDs account for over ninety percent of PUD cases, other less common but important etiologies must be considered. These secondary causes include the rare condition known as Zollinger-Ellison syndrome (ZES), characterized by a gastrin-producing tumor (gastrinoma), which leads to excessive secretion of gastric acid, often resulting in severe, multiple, or unusually located ulcers. Furthermore, certain lifestyle factors act as significant cofactors. Cigarette smoking dramatically impedes ulcer healing, increases recurrence rates, and may make treatment less effective by impairing mucosal blood flow and bicarbonate secretion. Although often historically blamed as the primary cause, psychological stress and dietary habits (such as consumption of spicy foods) are generally considered secondary risk factors that may exacerbate symptoms or impair healing, rather than initiating the ulcer formation themselves.

Historical Understanding and Key Discoveries

The earliest documented understanding of peptic ulcers dates back to the 19th century, though the underlying cause remained elusive for decades. In 1842, the German physician Rudolf Virchow played a pivotal role in the early pathology of the disease. Virchow recognized that ulcers resulted from localized destruction of tissue, suggesting that the condition was caused by external factors that eroded the mucosal lining, rather than being purely an internal, inflammatory process. He hypothesized that the damage was linked to circulatory disturbances or defects in the tissue’s ability to resist digestion by its own juices—a concept often referred to as autodigestion. This early framework established the importance of understanding the balance between aggressive and defensive factors in the stomach environment and moved the study away from purely systemic causes.

Moving into the early 20th century, the British physician Sir William Osler provided comprehensive clinical descriptions of the symptoms associated with peptic ulcers, furthering the clinical recognition of the condition. Osler, along with many contemporaries, suggested that peptic ulcers might be related to infectious processes, though the specific pathogen remained unidentified, and acid hypersecretion continued to be the primary focus of therapeutic interventions. For much of the 20th century, treatment focused heavily on managing acid levels through diet, antacids, and surgical interventions aimed at reducing acid production, such as vagotomy or partial gastrectomy, which carried significant morbidity. The introduction of H2-receptor antagonists in the 1970s marked a major advance, offering effective medical acid suppression for the first time, yet recurrence rates remained high.

The paradigm shift in the understanding and treatment of PUD occurred dramatically in 1982, spearheaded by the Australian researchers Barry Marshall and Robin Warren. Warren, a pathologist, first observed small, curved bacteria colonizing the gastric mucosa in patients with gastritis and ulcers. Marshall, a clinician, daringly ingested a culture of the organism (later named H. pylori) to fulfill Koch’s postulates, subsequently developing acute gastritis that was cured by antibiotics. Their monumental discovery established the undeniable causal link between the Helicobacter pylori bacterium and chronic gastritis and peptic ulcer disease. Initially met with skepticism, their findings eventually revolutionized clinical practice, transforming PUD from a chronic, relapsing condition requiring acid-suppression therapy into an infectious disease curable with antibiotics. Marshall and Warren were jointly awarded the Nobel Prize in Physiology or Medicine in 2005 for this life-saving work, cementing their legacy in gastroenterology.

Clinical Characteristics and Symptom Presentation

The hallmark clinical manifestation of peptic ulcer disease is upper abdominal pain, often localized to the epigastrium. Patients typically describe this discomfort as a dull ache, a gnawing sensation, or intense burning pain, which is directly related to the acid irritating the ulcerated tissue. A critical element of diagnosis involves understanding the timing of this pain in relation to meals, as this can often help differentiate between duodenal and gastric ulcers. Duodenal ulcer pain classically occurs two to five hours after eating, or during the night when acid secretion is high, and is characteristically relieved almost immediately by the ingestion of food, milk, or antacids, only to recur as the stomach empties, reflecting the typical pattern of acid neutralization and subsequent rebound.

Conversely, the presentation of gastric ulcers is often less predictable and potentially more severe. Pain associated with gastric ulcers may frequently be aggravated by eating, leading patients to develop “food aversion” and subsequent weight loss, though this pattern is not universal. Other common symptoms, regardless of ulcer location, include heartburn (dyspepsia), belching, and early satiety. Nausea and vomiting are also common, particularly if the ulcer is located near the pylorus, causing mechanical obstruction due to inflammation or scarring. It is important to note that a significant proportion of ulcers, especially those induced by NSAIDs, may be asymptomatic, particularly in older individuals, presenting instead with sudden, severe complications.

The most serious clinical characteristics of PUD relate to the development of complications, which require emergency medical intervention. The most frequent and life-threatening complication is gastrointestinal hemorrhage, which manifests as hematemesis (vomiting blood, which may look like coffee grounds) or melena (black, tarry stools due to digested blood), indicating the presence of a bleeding ulcer. Other grave complications include perforation, where the ulcer erodes entirely through the stomach or intestinal wall, leading to peritonitis and severe, sudden abdominal pain, often described as stabbing. Finally, chronic inflammation and scarring, particularly in duodenal ulcers, can lead to gastric outlet obstruction, preventing the normal passage of food and causing intractable vomiting and dehydration. The presence of black or bloody stools is always a critical red flag indicating potential bleeding and necessitates immediate investigation.

Diagnosis and Diagnostic Procedures

The definitive diagnosis of peptic ulcer disease relies on a combination of clinical assessment and specific diagnostic procedures aimed at visualizing the ulcer and determining the underlying etiology. The gold standard for diagnosis is esophagogastroduodenoscopy (EGD), or upper endoscopy. This minimally invasive procedure allows a gastroenterologist to directly visualize the esophagus, stomach, and duodenum, precisely locate the ulcer, assess its size and depth, and look for signs of active bleeding. EGD is essential because it not only confirms the presence of the ulcer but also allows for therapeutic intervention in the case of bleeding and permits the crucial step of tissue biopsy to rule out malignancy, which is a particular concern with gastric ulcers.

Identifying the presence of H. pylori is paramount for guiding treatment, and several non-invasive tests are available, typically utilized either as screening tools or as confirmation tests following eradication therapy. The Urea Breath Test (UBT) is highly accurate; the patient ingests a labeled urea solution, and if H. pylori is present, the urease enzyme metabolizes the urea, releasing labeled carbon dioxide that is detected in the patient’s breath. Another common non-invasive method is the Stool Antigen Test, which detects H. pylori antigens in the feces and offers comparable accuracy to the UBT. While widely available, serology (blood tests) to detect H. pylori antibodies is generally less useful for monitoring treatment efficacy, as antibodies can remain present in the blood long after the infection has been successfully eradicated, making it unreliable for confirming cure.

In cases where EGD is not immediately warranted or feasible, or to screen for underlying causes, specific blood work and imaging studies may be performed. Complete blood counts (CBC) are essential to check for iron-deficiency anemia resulting from chronic, slow blood loss. Furthermore, in the presence of severe, recurrent, or unusually positioned ulcers, particularly if refractory to standard treatment, the clinician may suspect Zollinger-Ellison syndrome (ZES). In this situation, blood tests measuring fasting serum gastrin levels are performed, often in conjunction with a secretin stimulation test to confirm the diagnosis of a gastrinoma. Barium swallow X-rays, while largely superseded by endoscopy, can still reveal ulcer craters or signs of gastric outlet obstruction, though they lack the ability to biopsy tissue.

Management and Pharmacological Treatment

The management of peptic ulcer disease is tailored specifically to the underlying cause, with the primary goals being eradication of H. pylori (if present), reduction of gastric acid secretion, symptom relief, and prevention of recurrence and complications. For ulcers confirmed to be caused by H. pylori, eradication therapy is the cornerstone of treatment. Standard initial regimens typically involve triple therapy, consisting of a proton pump inhibitor (PPI) coupled with two different antibiotics, such as amoxicillin and clarithromycin, administered for 10 to 14 days. Due to increasing global rates of antibiotic resistance, particularly to clarithromycin and metronidazole, sequential or quadruple therapy (involving a PPI, bismuth, metronidazole, and tetracycline) is increasingly used as first-line treatment in high-resistance areas or as salvage therapy following failed initial regimens.

Regardless of the etiology, acid-suppression therapy is critical for ulcer healing. Proton Pump Inhibitors (PPIs), such as omeprazole, lansoprazole, or pantoprazole, are the most potent acid suppressants available. They work by irreversibly inhibiting the H+/K+-ATPase pump in gastric parietal cells, effectively shutting down the final step in acid secretion. PPIs are generally prescribed for four to eight weeks to ensure complete ulcer healing and are also used routinely during H. pylori eradication protocols to enhance the efficacy of the antibiotics. Historically, H2-receptor antagonists (H2 blockers), which reduce acid output by blocking histamine’s action, were used, but their lower potency means they are now often reserved for mild symptoms or maintenance therapy rather than acute ulcer treatment.

For patients with NSAID-induced ulcers, the most crucial intervention is the immediate discontinuation of the offending NSAID, if clinically possible. If NSAIDs must be continued (e.g., low-dose aspirin for cardiac protection), strong prophylactic measures are necessary, usually involving co-prescription of a potent PPI or, less commonly, misoprostol, a synthetic prostaglandin analog. Managing acute complications, particularly severe gastrointestinal bleeding, requires immediate emergency care, often involving endoscopic intervention to stop the bleeding through thermal coagulation, application of clips, or injection of vasoactive agents. In severe cases of perforation or massive hemorrhage unresponsive to endoscopic control, surgical repair (e.g., oversewing the ulcer or patch repair) may be required to stabilize the patient and prevent life-threatening sepsis.

Lifestyle Modifications and Prognosis

While pharmacological treatment addresses the primary pathological mechanisms of peptic ulcer disease, long-term healing and prevention of recurrence depend heavily on significant and sustained lifestyle modifications. Among these, the most critical change is smoking cessation. Extensive clinical evidence demonstrates that cigarette smoking not only significantly increases the risk of developing PUD but also severely impairs the healing process, increases the likelihood of relapse, and diminishes the effectiveness of pharmacological treatments. Nicotine constricts blood vessels, thereby reducing mucosal blood flow, and may also impair the production of protective bicarbonate and prostaglandins, fundamentally undermining the stomach’s natural defense mechanisms against acid.

Dietary adjustments, while not the direct cause of PUD, often play a role in symptom management and reducing mucosal irritation. Patients are generally advised to avoid foods and beverages that are known to stimulate acid secretion or irritate the ulcer, such as highly acidic foods, concentrated citrus juices, and excessive consumption of alcohol. Alcohol consumption directly irritates the gastric mucosa, increases acid production, and can contribute to mucosal injury, thereby delaying healing. Furthermore, minimizing the intake of highly spiced foods, though varying individually, may help alleviate dyspeptic symptoms. Maintaining a balanced diet and avoiding late-night eating can also contribute positively to overall GI health.

The prognosis for peptic ulcer disease has dramatically improved since the introduction of H. pylori eradication therapy. Once a chronic, relapsing condition requiring lifetime antacid use, PUD is now largely curable. Successful eradication of H. pylori results in healing rates exceeding 90% and significantly reduces the risk of recurrence and associated complications, including the long-term risk of developing gastric cancer. However, patients must be carefully monitored, especially those with ulcers refractory to initial treatment or those identified with risk factors for malignancy. Long-term monitoring and follow-up endoscopy may be required to confirm healing and ensure that risk factors, particularly NSAID use, are managed appropriately. Patient education regarding medication adherence and the necessity of sustaining lifestyle changes is paramount for achieving a favorable and lasting outcome.

Conclusion

Peptic ulcer disease involves the formation of painful sores in the lining of the esophagus, stomach, or small intestine, resulting from an imbalance between aggressive factors, such as acid and pepsin, and the mucosal defense mechanisms. The vast majority of ulcers are caused by infection with the Helicobacter pylori bacterium or the chronic use of NSAIDs. Symptoms typically include a burning or gnawing abdominal pain, often accompanied by nausea, vomiting, and heartburn. Untreated, PUD can lead to severe complications including hemorrhage, perforation, and obstruction, underscoring the necessity of accurate diagnosis via endoscopy and non-invasive tests.

The revolutionary discovery by Marshall and Warren established the infectious nature of PUD, fundamentally altering treatment protocols. Modern management focuses on the complete eradication of H. pylori using combination antibiotic and potent PPI regimens, coupled with robust acid suppression therapy to facilitate healing. For NSAID-related ulcers, cessation of the medication and concurrent PPI use are essential for preventing recurrence. Crucial to long-term success is the adoption of critical lifestyle changes, most notably quitting smoking and limiting alcohol intake, which significantly impact healing rates and recurrence risk. With effective treatment and adherence to medical advice, peptic ulcer disease is highly manageable, leading to excellent long-term prognosis for most patients.

References

  • Hume, A.L. (2015). Peptic Ulcer Disease. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.

  • González, C.A., & Barberán, J. (2004). Ulcer history: From Virchow to Marshall and Warren. World Journal of Gastroenterology, 10(5), 613–618. https://doi.org/10.3748/wjg.v10.i5.613

  • Dalvi, P. (2020). Peptic Ulcers: Causes, Symptoms, and Treatment. Retrieved from https://www.healthline.com/health/peptic-ulcer

  • Vakil, N. (2020). Peptic Ulcer Disease. Retrieved from https://www.merckmanuals.com/professional/gastrointestinal-disorders/gastritis-and-peptic-ulcer-disease/peptic-ulcer-disease

  • Laine, L., & Schoenfeld, P. (2000). A systematic review of H. pylori eradication regimens. Alimentary Pharmacology & Therapeutics, 14(Suppl 3), 6–13.